NCT06278077View on ClinicalTrials.gov

Neurexan - a Clinical Trial in Short-Term Insomnia Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 4, 2023

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
InsomniaStress Reaction
Interventions
DRUG

Neurexan

The active ingredients are Passiflora incarnata Dil. D2 (0.6 mg / tablet), Avena sativa Dil. D2 (0.6 mg / tablet), Coffea arabica Dil. D12 (0.6 mg/tablet) and Zincum isovalerianicum Dil. D4 (0.6 mg / tablet). Inactive excipients are lactose monohydrate and magnesium stearate.

DRUG

Placebo

Contains lactose monohydrate, magnesium stearate and looks identical to Neurexan in terms of taste, size, color and labelling.

Trial Locations (1)

07743

RECRUITING

Jena University Hospital, Department of Psychiatry & Psychotherapy, Jena

All Listed Sponsors
lead

Biologische Heilmittel Heel GmbH

INDUSTRY